Risen Pharma Tech

Executive Summary

Risen Pharma Tech is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on developing innovative small molecule and siRNA therapeutics across three core therapeutic areas: orthopedics (osteoarthritis), oncology, and neuroscience (Alzheimer's disease). Founded in 2020, the company has rapidly established two R&D centers in China, integrating capabilities in target validation, high-throughput screening, drug design, and translational medicine. With a team of 50-200 employees, Risen advances a pipeline of novel drug candidates, currently in Phase 2 clinical trials, aiming to address significant unmet medical needs in these high-prevalence diseases. The company's lead program targets osteoarthritis, a degenerative joint disease affecting millions worldwide, with potential disease-modifying benefits. In oncology, Risen is developing next-generation small molecule inhibitors, while in neuroscience, its siRNA approach for Alzheimer's disease offers a novel mechanism to modulate disease progression. As a private, clinical-stage entity, Risen Pharma Tech represents an emerging player in China's growing biotech landscape, with its integrated platform and diversified pipeline positioning it for potential value creation through data readouts and strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for osteoarthritis candidate65% success
• Q4 2026Initiation of Phase 1/2 trial for Alzheimer's siRNA therapy50% success
• TBDPotential licensing or collaboration deal for oncology pipeline30% success